A Phase 4 interventional study of Decongestant nasal spray (oxymetazoline hydrochloride (0.05%)) and PLACEBO: 2.5mL of normal saline 0.9% and benzalkonium chloride 0.02% in Perioperative Respiratory Adverse Events and Anesthesia Outcomes, sponsored by Telethon Kids Institute. Recruiting at 1 site in Australia. Open to participants aged 1 Year to 8 Years. Per ClinicalTrials.gov, last updated 2025-11-19.
Sponsored by Telethon Kids Institute · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Respiratory Tract Infections with a site in Australia — 5 open to participants now, 6 under way, 2 of them phase 3. Respiratory Tract Infections · Australia.
Among the 29 studies in Respiratory Tract Infections with a site in Australia, this one is the 11th largest by planned enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2025, is one of 3 in phase 4, and was the 27th registered.
753 studies on the registry are indexed under Respiratory Tract Infections; 112 are open to participants now.
Browse Respiratory Tract Infections studies →5 of the 29 studies in Respiratory Tract Infections with a site in Australia are open now. Recruiting first, the newest first:
Murdoch Childrens Research Institute · Sites in Australia
Ages 1–17
Murdoch Childrens Research Institute · Sites in Australia
Ages 4–17
AstraZeneca · Sites in Australia, United States, Argentina and 36 more countries
Ages 18+
UMC Utrecht · Sites in Australia, United States, Belgium and 26 more countries
Ages 28 days+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 73 Respiratory Tract Infections studies recruiting now, 33 (45%) set no upper age limit and 32 (44%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 1 Year to 8 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 7 · Phase 4 3
First in 2006; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 200 across 542 interventional studies indexed under Respiratory Tract Infections.
Median enrollment 189 across the 27 interventional studies, 656 across the 2 observational. Of the 22 that completed or were terminated, 8 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 29 have an industry lead sponsor. The 10 most frequent:
Telethon Kids Institute is the lead sponsor of 12 studies on the registry; 6 are open to participants now.
Telethon Kids Institute has 1 study filed under Respiratory Tract Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in Respiratory Tract Infections with a site in Australia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT07093749Murdoch Childrens Research InstitutePerspectives on Antibiotics and Tracking Symptoms in Children | 2026-11 |
| NCT06953804University of WollongongOptimal Implementation of Antimicrobial Stewardship in General Practice | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 29 studies in Respiratory Tract Infections with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this multicentre, double-blind, randomised controlled trial study is to learn if the use of a nasal spray to open the nasal passages and increase airflow before surgery can reduce the occurrence of perioperative respiratory adverse events in children with upper respiratory tract infection who are undergoing anesthesia.
The main questions it aims to answer are:
Participants will:
Upper respiratory tract infections (URTI), including COVID-19 infection and the common cold, are common and frequent in children who present for elective surgery. Children with URTI are at a two-to-three-fold increased risk of perioperative respiratory adverse events (PRAE). PRAE are among the most serious and impactful consequences of paediatric anesthesia, including cardio-respiratory arrest, and therefore present a significant challenge for the pediatric anesthetist.
This two-phase, multicentre, international, double-blinded, randomised controlled trial aims to improve the safety of children with upper respiratory tract infections undergoing anesthesia by investigating the use of a nasal spray pre-operatively to reduce respiratory complications. Following informed written parental consent, 200 pediatric patients aged 1 to 8 years, undergoing general anesthesia for any surgery with current or recent URTI will be randomised to receive at the induction of anesthesia either a decongestant nasal spray or a placebo spray using the same bottle/actuator.
Monitoring and recording of PRAE (laryngospasm - closure of the vocal cords, bronchospasm - narrowing of the airways, severe and persistent coughing, airway obstruction, oxygen desaturation (\<95%) and postoperative stridor-squeaky noises when breathing) will occur throughout the procedure and in the post anesthesia care unit (PACU). We hypothesise that children who receive the nasal decongestant will be at a reduced risk of developing PRAE.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Decongestant nasal spray, oxymetazoline (0.05%). Specific: 2.5mL of oxymetazoline 0.05% dispensed into amber brown 15ml bottles with pump and actuator attached. Children aged 1 to 5.99 years will receive 1 spray of either the nasal decongestant or placebo into each nostril, while children aged 6 years and above will receive 2 spays per nostril. Administration will be recorded on the standard patient's Medication Chart.
Drug: Decongestant nasal spray (oxymetazoline hydrochloride (0.05%))
Matched Placebo spray. Specific: 2.5mL of normal saline 0.9% and benzalkonium chloride 0.02% dispensed into amber brown 15ml bottles with pump and actuator attached. Dose: children aged 1 to 5.99 years will receive 1 spray of either the nasal decongestant or placebo into each nostril, while children aged 6 years and above will receive 2 spays per nostril. Administration will be recorded on the standard patient's Medication Chart.
Drug: PLACEBO: 2.5mL of normal saline 0.9% and benzalkonium chloride 0.02%
Decongestant nasal spray containing active ingredient.
Control nasal spray containing no active ingredient.
Incidence of perioperative respiratory adverse event (PRAE) following the delivery of a nasal decongestant (Oxymetazoline 0.05%) or placebo prior to surgery under anesthesia in children with upper respiratory tract infection
PRAE will be defined as laryngospasm, bronchospasm, severe persistant coughing, hypoxaemia (\<95% for at least 10 seconds), airway obstruction, stridor or pulmonary aspiration. Incidence will be assessed by the clinician caring for the patient. Incidence is binary - yes if PRAE occured, no otherwise.
Time frame: On day of surgery: Perioperative period. PRAE will be assessed if it occurs anywhere along the perioperative pathway between the beginning of the patient's emergence from anesthesia and their discharge from the post-anesthetic care unit (PACU)
Assess the incidence of severe PRAE during emergence or in PACU in children who received the decongestant spray compared to the control group.
Severe PRAE is defined as laryngospasm or bronchospasm, as assessed by the clinician caring for the patient.
Time frame: Day of surgery: Perioperative period. Severe PRAE will be assessed if it occurs anywhere along the perioperative pathway between the beginning of the patient's emergence from anesthesia and their discharge from the post-anesthetic care unit (PACU)
Assess the incidence of minor PRAE during emergence or in PACU inchildren who recieved the decongestant spray compared to the control group.
Minor PRAE is defined as severe coughing, desaturation \<95% for at least 10 seconds, airway obstruction, stridor or pulmonary aspiration, as assessed by the clinician caring for the patient.
Time frame: Day of surgery: Perioperative period. Minor PRAE will be assessed if it occurs anywhere along the perioperative pathway between the beginning of the patient's emergence from anesthesia and their discharge from the post-anesthetic care unit (PACU)
Evaluate the acceptability of nasal decongestant use at the induction of anesthesia in children with upper respiratory tract infection aged 4 and older and their parents/guardians
Children aged 4 and over and their parents/guardians will be asked to rate the acceptibility of the intervention using a 5-point Likert scale (1 = completely unacceptable; 5 = completely acceptable).
Time frame: Patients and parents/guardians will be asked to rate the intervention post-operatively, prior to their discharge from hospital.
Evaluate the acceptability of nasal decongestant use at the induction of anesthesia by the treating anaesthetist
Treating anaesthetists will be asked to rate the acceptibility of the intervention on a 5-point Likert scale (1 = completely unacceptable; 5 = completely acceptable)
Time frame: Treating anaesthetists will be asked to rate the intervention immediately after the administration of the interventional product.
Incidence of any potential adverse effects related to the administration of the nasal decongestant/placebo
Any potential adverse effects will be recorded as per the study doctor and the clinical team caring for the patient.
Time frame: Any potential adverse effects will be assessed from the administration of the interventional product until the patient's discharge from hospital.
Assessment of the successful administration of the interventional product in children
This will be based upon the clinical judgement of the treating anesthesia clinician.
Time frame: Successful administration of the interventional product will be assessed by the study team at induction of anesthesia, immediately following the administration or attempted administration of the nasal decongestant or placebo.
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for May 2028, 35 months after the start.
Of 29 phase 4 interventional studies under Respiratory Tract Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 51. This study's planned 35 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Tract Infections →
Telethon Kids Institute